Clinical Trials Logo

Filter by:
NCT ID: NCT00044577 Completed - HIV Infection Clinical Trials

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Start date: July 16, 2002
Phase: Phase 3
Study type: Interventional

A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.

NCT ID: NCT00044512 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Start date: August 2002
Phase: Phase 2
Study type: Interventional

Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.

NCT ID: NCT00044421 Completed - Diabetes Mellitus Clinical Trials

Treatment of Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00044395 Completed - Clinical trials for Diabetic Neuropathies

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00044070 Completed - Clinical trials for Cerebrovascular Accident

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

Start date: December 2000
Phase: Phase 2
Study type: Interventional

This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke. The study will determine if a 24-hour infusion of YM872, given within 6 hours of stroke onset, reduces the ischemic lesion volume as measured by MRI at 28 days after the infusion is given. The clinical effects of YM872 will also be determined by neurological function and disability scores at follow up visits through Day 90 of the study.

NCT ID: NCT00044057 Completed - Clinical trials for Acute Ischemic Stroke

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Start date: December 2000
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study.

NCT ID: NCT00043927 Completed - Clinical trials for Small Cell Lung Cancer

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Start date: April 2001
Phase: Phase 3
Study type: Interventional

This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.

NCT ID: NCT00042068 Completed - Clinical trials for Arthritis, Rheumatoid

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

Start date: June 2002
Phase: Phase 3
Study type: Interventional

A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

NCT ID: NCT00041301 Completed - Prostate Cancer Clinical Trials

Assessing Quality of Life of Patients With Prostate Cancer

Start date: March 2002
Phase: N/A
Study type: Observational

RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate and long-term effects of the treatment on these patients. PURPOSE: Clinical trial to study the effectiveness of two questionnaires in assessing quality of life of patients who have prostate cancer.

NCT ID: NCT00041249 Completed - Sarcoma Clinical Trials

Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Start date: May 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally advanced or metastatic soft tissue sarcoma that has not responded to one previous chemotherapy regimen.